Results 121 to 130 of about 16,507 (152)

The cardioprotective effects of mineralocorticoid receptor antagonists

Pharmacology & Therapeutics, 2014
Despite state-of-the-art reperfusion therapy, morbidity and mortality remain significant in patients with an acute myocardial infarction. Therefore, novel strategies to limit myocardial ischemia-reperfusion injury are urgently needed. Mineralocorticoid receptor (MR) antagonists are attractive candidates for this purpose, since several clinical trials ...
van den Berg, T.N.A., van den Berg, T.N.A., Rongen, G.A.P.J.M., Rongen, G.A.P.J.M., Rongen, G.A.P.J.M., Frohlich, G.M., Deinum, J., Deinum, J., Hausenloy, D.J., Riksen, N.P., Riksen, N.P., Riksen, N.P., Riksen, N.P.   +12 more
openaire   +3 more sources

The renal effects of mineralocorticoid receptor antagonists

International Journal of Cardiology, 2015
Beyond its well known classic effects on renal water and electrolytes metabolism, an increasing amount of experimental and clinical evidence suggests that aldosterone contributes to the pathogenesis and progression of kidney disease. The binding of aldosterone on epithelial and non-epithelial cells of the kidney induces many deleterious effects, such ...
Stefano, Bianchi, Valentina, Batini, Roberto, Bigazzi   +2 more
openaire   +2 more sources

Role of mineralocorticoid receptor antagonists in kidney diseases

Drug Development Research, 2020
AbstractMineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Increasing evidence suggests that mineralocorticoid receptor activation causes the pathogenesis and progression of chronic kidney disease.
Vishal Patel, Amit Joharapurkar, Mukul Jain   +2 more
openaire   +2 more sources

Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone

Current Cardiology Reports, 2020
We aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently under investigation for its promising cardiovascular and nephrological effects.MRAs are well known for ...
Juan Simon, Rico-Mesa, Averi, White, Ashkan, Ahmadian-Tehrani, Allen S, Anderson   +3 more
openaire   +2 more sources

Emerging cardiovascular indications of mineralocorticoid receptor antagonists

Trends in Endocrinology & Metabolism, 2015
Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions.
Parviz, Yasir, Iqbal, Javaid, Pitt, Bertram, Adlam, David, Al-Mohammad, Abdallah, Zannad, Faiez   +5 more
openaire   +2 more sources

Adverse Effects of Mineralocorticoid Receptor Antagonist Administration

Current Pharmaceutical Design, 2019
Background: Mineralocorticoid receptor antagonists consist of a class of drugs with pleiotropic beneficial effects in several cardiovascular diseases. However, physicians frequently overlook their use due to the adverse effects of such agents. Objectives: To determine the adverse effects of mineralocorticoid receptor antagonists and to suggest ...
Manolis S, Kallistratos, Andreas, Pittaras, Iakovos, Theodoulidis, Charris, Grassos, Leonidas E, Poulimenos, Athanasios J, Manolis   +5 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists (MRAs)

2014
Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...
Roy S. Gardner, Theresa A. McDonagh, Niki L. Walker   +2 more
openaire   +1 more source

Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences

Current Opinion in Pharmacology, 2016
Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use;
Jun, Yang, Morag J, Young
openaire   +2 more sources

Mineralocorticoid Receptor Antagonists: An Overview of History and Evolution

Journal of The Association of Physicians of India
Mineralocorticoid receptor antagonists (MRAs) have significantly evolved since the introduction of the first steroidal MRA, spironolactone, in the 1950s. Initially discovered for treating hypertension and heart failure (HF), the clinical applications of MRAs have been expanded to chronic kidney disease (CKD) and diabetic nephropathy.
B C, Kalmath, Mangesh, Tiwaskar, Gattu R, Kumar, Hemant, Khemani, Amit, Singh, Rajeev, Kishore, Arvind, Chouhan, B L, Harikrishnan, Sarita, Choudhary, Manish, Goyal, Arun, Pradhan, Febin, Francis, Amarnath, Sugumaran, Senthilnathan, Mohanasundaram   +13 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists (MRAs)

Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...
Roy S. Gardner, Theresa A. McDonagh, Daniel J. Doherty, Nikki L. Walker   +3 more
openaire   +1 more source